Application of an ATP-bioluminescence assay in human tumor chemosensitivity testing

B. U. Sevin, Z. L. Peng, J. P. Perras, P. Ganjei, M. Penalver, H. E. Averette

Research output: Contribution to journalArticle

125 Citations (Scopus)

Abstract

Intracellular adenosine triphosphate (ATP) is the primary energy unit of living cells, and can be quantitated by measuring the light generated with luciferase-luciferin reagent in a luminometer. The use of an ATP-bioluminescence assay, to determine tumor cell viability after exposure to chemotherapeutic agents, has been adapted to test tumor chemosensitivity in vitro. This presentation will illustrate the method of the ATP-chemosensitivity assay (ATP-CSA) using an ovarian cancer cell line NIHL: OVCAR-3 as an example and present preliminary data on 54 56 successful in vitro ATP-CSA's from 46 patients with pelvic malignancies. Fresh human tumor specimens were generally tested for single and combined drug effects at two drug concentrations (0.2 × and 1 × peak plasma concentrations). Correlation of in vitro drug sensitivity and in vivo patient response was obtained for 23 treatment regimens in 22 patients with ovarian carcinoma. The true positive rate was 100% and the true negative rate 66.7%. Our data demonstrate (a) that the ATP-CSA, measuring total cell viability, is a feasible in vitro assay for human tumor drug testing and (b) that specific criteria of in vitro chemosensitivity for this assay need to be defined by further studies, for single and combined drug exposure at different concentrations, to permit a meaningful correlation with in vivo clinical response.

Original languageEnglish
Pages (from-to)191-204
Number of pages14
JournalGynecologic Oncology
Volume31
Issue number1
DOIs
StatePublished - Jan 1 1988

Fingerprint

Adenosine Triphosphate
Pharmaceutical Preparations
Neoplasms
Cell Survival
Luciferases
Ovarian Neoplasms
In Vitro Techniques
Carcinoma
Light
Cell Line
Therapeutics

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Sevin, B. U., Peng, Z. L., Perras, J. P., Ganjei, P., Penalver, M., & Averette, H. E. (1988). Application of an ATP-bioluminescence assay in human tumor chemosensitivity testing. Gynecologic Oncology, 31(1), 191-204. https://doi.org/10.1016/0090-8258(88)90293-4

Application of an ATP-bioluminescence assay in human tumor chemosensitivity testing. / Sevin, B. U.; Peng, Z. L.; Perras, J. P.; Ganjei, P.; Penalver, M.; Averette, H. E.

In: Gynecologic Oncology, Vol. 31, No. 1, 01.01.1988, p. 191-204.

Research output: Contribution to journalArticle

Sevin, BU, Peng, ZL, Perras, JP, Ganjei, P, Penalver, M & Averette, HE 1988, 'Application of an ATP-bioluminescence assay in human tumor chemosensitivity testing', Gynecologic Oncology, vol. 31, no. 1, pp. 191-204. https://doi.org/10.1016/0090-8258(88)90293-4
Sevin, B. U. ; Peng, Z. L. ; Perras, J. P. ; Ganjei, P. ; Penalver, M. ; Averette, H. E. / Application of an ATP-bioluminescence assay in human tumor chemosensitivity testing. In: Gynecologic Oncology. 1988 ; Vol. 31, No. 1. pp. 191-204.
@article{19d68a87a49e4ddf82887f4505e3fe56,
title = "Application of an ATP-bioluminescence assay in human tumor chemosensitivity testing",
abstract = "Intracellular adenosine triphosphate (ATP) is the primary energy unit of living cells, and can be quantitated by measuring the light generated with luciferase-luciferin reagent in a luminometer. The use of an ATP-bioluminescence assay, to determine tumor cell viability after exposure to chemotherapeutic agents, has been adapted to test tumor chemosensitivity in vitro. This presentation will illustrate the method of the ATP-chemosensitivity assay (ATP-CSA) using an ovarian cancer cell line NIHL: OVCAR-3 as an example and present preliminary data on 54 56 successful in vitro ATP-CSA's from 46 patients with pelvic malignancies. Fresh human tumor specimens were generally tested for single and combined drug effects at two drug concentrations (0.2 × and 1 × peak plasma concentrations). Correlation of in vitro drug sensitivity and in vivo patient response was obtained for 23 treatment regimens in 22 patients with ovarian carcinoma. The true positive rate was 100{\%} and the true negative rate 66.7{\%}. Our data demonstrate (a) that the ATP-CSA, measuring total cell viability, is a feasible in vitro assay for human tumor drug testing and (b) that specific criteria of in vitro chemosensitivity for this assay need to be defined by further studies, for single and combined drug exposure at different concentrations, to permit a meaningful correlation with in vivo clinical response.",
author = "Sevin, {B. U.} and Peng, {Z. L.} and Perras, {J. P.} and P. Ganjei and M. Penalver and Averette, {H. E.}",
year = "1988",
month = "1",
day = "1",
doi = "10.1016/0090-8258(88)90293-4",
language = "English",
volume = "31",
pages = "191--204",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Application of an ATP-bioluminescence assay in human tumor chemosensitivity testing

AU - Sevin, B. U.

AU - Peng, Z. L.

AU - Perras, J. P.

AU - Ganjei, P.

AU - Penalver, M.

AU - Averette, H. E.

PY - 1988/1/1

Y1 - 1988/1/1

N2 - Intracellular adenosine triphosphate (ATP) is the primary energy unit of living cells, and can be quantitated by measuring the light generated with luciferase-luciferin reagent in a luminometer. The use of an ATP-bioluminescence assay, to determine tumor cell viability after exposure to chemotherapeutic agents, has been adapted to test tumor chemosensitivity in vitro. This presentation will illustrate the method of the ATP-chemosensitivity assay (ATP-CSA) using an ovarian cancer cell line NIHL: OVCAR-3 as an example and present preliminary data on 54 56 successful in vitro ATP-CSA's from 46 patients with pelvic malignancies. Fresh human tumor specimens were generally tested for single and combined drug effects at two drug concentrations (0.2 × and 1 × peak plasma concentrations). Correlation of in vitro drug sensitivity and in vivo patient response was obtained for 23 treatment regimens in 22 patients with ovarian carcinoma. The true positive rate was 100% and the true negative rate 66.7%. Our data demonstrate (a) that the ATP-CSA, measuring total cell viability, is a feasible in vitro assay for human tumor drug testing and (b) that specific criteria of in vitro chemosensitivity for this assay need to be defined by further studies, for single and combined drug exposure at different concentrations, to permit a meaningful correlation with in vivo clinical response.

AB - Intracellular adenosine triphosphate (ATP) is the primary energy unit of living cells, and can be quantitated by measuring the light generated with luciferase-luciferin reagent in a luminometer. The use of an ATP-bioluminescence assay, to determine tumor cell viability after exposure to chemotherapeutic agents, has been adapted to test tumor chemosensitivity in vitro. This presentation will illustrate the method of the ATP-chemosensitivity assay (ATP-CSA) using an ovarian cancer cell line NIHL: OVCAR-3 as an example and present preliminary data on 54 56 successful in vitro ATP-CSA's from 46 patients with pelvic malignancies. Fresh human tumor specimens were generally tested for single and combined drug effects at two drug concentrations (0.2 × and 1 × peak plasma concentrations). Correlation of in vitro drug sensitivity and in vivo patient response was obtained for 23 treatment regimens in 22 patients with ovarian carcinoma. The true positive rate was 100% and the true negative rate 66.7%. Our data demonstrate (a) that the ATP-CSA, measuring total cell viability, is a feasible in vitro assay for human tumor drug testing and (b) that specific criteria of in vitro chemosensitivity for this assay need to be defined by further studies, for single and combined drug exposure at different concentrations, to permit a meaningful correlation with in vivo clinical response.

UR - http://www.scopus.com/inward/record.url?scp=0023790164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023790164&partnerID=8YFLogxK

U2 - 10.1016/0090-8258(88)90293-4

DO - 10.1016/0090-8258(88)90293-4

M3 - Article

C2 - 3410347

AN - SCOPUS:0023790164

VL - 31

SP - 191

EP - 204

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -